Because of their critical roles in inflammatory and metabolic pathways, synthetic PPAR agonists are widely used in patients with obesity associated disorders including dyslipidemia, type 2 diabetes mellitus (T2DM) and so on. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.